Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
TLDR
The spectrum of chemotherapy-induced peripheral neuropathy characteristics is discussed so as to highlight areas of future research to pursue on the topic and allow the registration and analysis of reliable data on the true characteristics of CIPN, eventually leading to potential preventive and therapeutic interventions.Abstract:
Commonly used chemotherapeutic agents in oncology/hematology practice, causing toxic peripheral neuropathy, include taxanes, platinum compounds, vinca alkaloids, proteasome inhibitors, and antiangiogenic/immunomodulatory agents. This review paper intends to put together and discuss the spectrum of chemotherapy-induced peripheral neuropathy (CIPN) characteristics so as to highlight areas of future research to pursue on the topic. Current knowledge shows that the pathogenesis of CIPN still remains elusive, mostly because there are several sites of involvement in the peripheral nervous system. In any case, it is acknowledged that the dorsal root ganglia of the primary sensory neurons are the most common neural targets of CIPN. Both the incidence and severity of CIPN are clinically under- and misreported, and it has been demonstrated that scoring CIPN with common toxicity scales is associated with significant inter-observer variability. Only a proportion of chemotherapy-treated patients develop treatment-emergent and persistent CIPN, and to date it has been impossible to predict high-and low-risk subjects even within groups who receive the same drug regimen. This issue has recently been investigated in the context of pharmacogenetic analyses, but these studies have not implemented a proper methodological approach and their results are inconsistent and not really clinically relevant. As such, a stringent approach has to be implemented to validate that information. Another open issue is that, at present, there is insufficient evidence to support the use of any of the already tested chemoprotective agents to prevent or limit CIPN. The results of comprehensive interventions, including clinical, neurophysiological, and pharmacogenetic approaches, are expected to produce a consistent advantage for both doctors and patients and thus allow the registration and analysis of reliable data on the true characteristics of CIPN, eventually leading to potential preventive and therapeutic interventions.read more
Citations
More filters
Journal ArticleDOI
Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy
Kerri M. Winters-Stone,Fay B. Horak,Peter G. Jacobs,Phoebe Trubowitz,Nathan F. Dieckmann,Sydnee Stoyles,Sara Faithfull +6 more
TL;DR: CIPN must be assessed earlier in the clinical pathway, and strategies to limit symptom progression and to improve function must be included in clinical and survivorship care plans.
Journal ArticleDOI
Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice.
TL;DR: SARM1 is established as the central determinant of a fundamental axonal degeneration pathway that is activated by diverse insults and it is suggested that targeting SARM1 or its downstream effectors may be a viable therapeutic option to prevent vincristine-induced peripheral polyneuropathy and possibly other peripheralpolyneuropathies.
Journal ArticleDOI
Chemotherapy-induced peripheral neuropathy: Current status and progress.
TL;DR: This review will briefly review the clinical presentation, evaluation and management of chemotherapy-induced peripheral neuropathy, with a focus on CIPN related to platinum and taxane agents.
Journal ArticleDOI
Platinum-Induced Neurotoxicity and Preventive Strategies: Past, Present, and Future
Abolfazl Avan,Tjeerd J. Postma,Cecilia Ceresa,Amir Avan,Guido Cavaletti,Elisa Giovannetti,Godefridus J. Peters +6 more
TL;DR: Dose adjustment and/or drug withdrawal seem to be the most frequently used methods in the management of platinum-induced peripheral neurotoxicity, and studies on in vitro models and appropriate trials planning should be integrated into the future design of neuroprotective strategies to find the best patient-oriented solution.
Journal ArticleDOI
Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy.
Preet G.S. Makker,Samuel S. Duffy,Justin G. Lees,Chamini J. Perera,Ryan S. Tonkin,Oleg Butovsky,Susanna B. Park,David Goldstein,Gila Moalem-Taylor +8 more
TL;DR: It is suggested that PTX and OXA cause distinct pathological changes in the periphery and nervous system, which may contribute to chemotherapy-induced neuropathic pain.
References
More filters
Journal ArticleDOI
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
A. de Gramont,A. Figer,M. Seymour,M. Homerin,A. Hmissi,J. Cassidy,Corrado Boni,H. Cortes-Funes,Andrés Cervantes,Gilles Freyer,Demetris Papamichael,N. Le Bail,C. Louvet,D. Hendler,F. de Braud,C. Wilson,Francois Morvan,Andrea Bonetti +17 more
TL;DR: The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Journal ArticleDOI
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau,Halyna Pylypenko,Sebastian Grosicki,Ievgenii Karamanesht,Xavier Leleu,Maria Grishunina,Grigoriy B Rekhtman,Zvenyslava Masliak,Tadeusz Robak,Anna V Shubina,Bertrand Arnulf,Martin Kropff,James Cavet,Dixie-Lee Esseltine,Huaibao Feng,Suzette Girgis,Helgi van de Velde,William Deraedt,Jean-Luc Harousseau +18 more
TL;DR: The primary objective was to show non-inferiority of subcutaneous versus intravenous bortezomib in terms of overall response rate (ORR) after four cycles in patients with a diagnosis of measurable, secretory multiple myeloma who received one or more dose of drug.
Journal ArticleDOI
Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial
Ellen M. Lavoie Smith,Herbert Pang,Constance Cirrincione,Stewart B. Fleishman,Electra D. Paskett,Tim A. Ahles,Linda R. Bressler,Camilo E. Fadul,Chetaye Knox,Nguyet Le-Lindqwister,Paul Gilman,Charles L. Shapiro,Charles L. Shapiro +12 more
TL;DR: Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain, and the primary hypothesis was that dulOxetine would be more effective than placebo in decreasing chemotherapy- induced peripheral neuropathic pain.
Journal ArticleDOI
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study
Christophe Tournigand,Andrés Cervantes,Arie Figer,Gérard Lledo,M. Flesch,Marc Buyse,Laurent Mineur,Elisabeth Carola,Pierre-Luc Etienne,Fernando Rivera,Isabel Chirivella,N. Perez-Staub,Christophe Louvet,Thierry André,Isabelle Tabah-Fisch,Aimery de Gramont +15 more
TL;DR: Oxaliplatin can be safely stopped after six cycles in a FOLFOX regimen, and further study is needed to fully evaluate oxali Platin reintroduction.
Related Papers (5)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman,Christina Lacchetti,Robert H. Dworkin,Ellen M. Lavoie Smith,Jonathan Bleeker,Guido Cavaletti,Cynthia Chauhan,Patrick Gavin,Antoinette Lavino,Maryam B. Lustberg,Judith A. Paice,Bryan P. Schneider,Mary Lou Smith,Thomas J. Smith,Shelby A. Terstriep,Nina D. Wagner-Johnston,Kate Bak,Charles L. Loprinzi +17 more